Primary prophylaxis for cryptococcal meningitis

HIV Medicine

Volumn 5, Issue 3, 2004, Pages 131-132

  John, Lawrence ^a   Nelson, Mark ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; FLUCONAZOLE; GENERIC DRUG; ITRACONAZOLE; PLACEBO; PYRROLE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; EDITORIAL; FUNGAL MENINGITIS; GEOGRAPHIC DISTRIBUTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LONGEVITY; MORTALITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROSPECTIVE PRICING; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SURVIVAL TIME;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; FLUCONAZOLE; HUMANS; MENINGITIS, CRYPTOCOCCAL; PRIMARY PREVENTION;

EID: 2942674448     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2004.00199.x     Document Type: Editorial

References (18)

1. Chariyalertsak S, Suparatpinyo K, Sirisanthana T et al. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 2002; 34: 277-284.
2. Powderly W, Finkelstein D, Feinberg J et al. A randomised trial with clotrimazole troches for the prevention of fungal infections in patients with advanced HIV infection. N Engl J Med 1995; 332: 700-705.
3. Mckinsey D, Wheat L, Cloud G. Itraconazole prophylaxis for fungal infections in patients with advanced HIV infection: randomised, placebo controlled, double blind study. Clin Infect Dis 1999; 28: 1049-1056.
4. Masur H, Kaplan J, Holmes K. Guidelines for preventing opportunistic infections among HIV infected persons. Ann Int Med 2002; 137: 435-477.
5. Anonymous. AIDS Epidemic Update December 2003. Joint United Nations Programme on HIV AIDS. http://www.unaids.org 2003.
6. Tansuphasawadikul S, Amornkul P, Tanchanpong C et al. Clinical presentation of hospitalised adult patients with HIV and AIDS in Bangkok. Thailand J AIDS 1999; 21: 326.
7. French N, Gray K, Waatera C et al. Cryptococcal infection in a cohort of HIV-1 infected adults. AIDS 2002; 16: 1031-1038.
8. Robinson P, Bauer M, Leal M et al. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999; 28: 82-92.
9. Heyderman R, Gangaidzo I, Hakim G et al. Cryptococcal meningitis in HIV infected patients in Harare, Zimbabwe. Clin Infect Dis 1998; 26: 284-289.
10. Primary prevention of invasive cryphococcal disease using fluconate prophylaxis in HIV infected Ugandan's. http://www.controlled-trials.com/sktn/trial/76481529/0/76481529.html
11. Chetchotisatkd P, Sungkanuparph S, Thinkhamrop B, Mootsikapun P, Boonyaprawit P. A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency. HIV Med; 2004 5: 139-142.
12. Havlir D, Dube M, McCutchan A et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis 1998; 27: 1369-1375.
13. Berg J, Clancy C, Nguyen M et al. The hidden danger of primary prophylaxis for patients with AIDS. Clin Infect Dis 1998; 26: 186-187.
14. Freedberg K, Scharfstein J, Seage G et al. The cost effectiveness of preventing AIDS related opportunistic infections. J Am Med Assoc 1998; 279: 130-136.
15. WHO. Uganda per Capita Total Expenditure on Health at Average Exchange Rate (US$). http://www3.who.int/whosis.
16. Anonymous. Price Differences of Fluconazole - Consequences and Conclusions. MSF Access Essential Medicines Campaign Study. http://www.accessmed-msf.org 2000.
17. Anonymous. WHO Welcomes Offer by Pfizer to Offer Fluconazole Free of Charge in Least Developed Countries. Statement WH0/10. 2001; http://www.who.int/inf-pr-2001/en/state2001-10.html/
18. Anonymous. Untangling the Web of Price Reductions: A Pricing Guide for the Purchase of ARVs for Developing Countries. Campaign for Access to Essential Medicines. 2002; http://www.accessmed-msf.org/